Research on new and better ways to treat cancer. Covers radiotherapy, targeted microdroplets, nerve-injury protection, drug combinations, and tumor models.
A research team has engineered bacteria capable of consuming tumours from the inside out, using a novel tool for cancer treatment. The bacteria, Clostridium sporogenes, are designed to multiply in oxygen-free environments found in solid tumours, where they can effectively target and destroy cancerous cells.
Scientists developed a new platform using protein-like polymers to target and degrade cancer-driving proteins like MYC and KRAS. The approach triggers cancer cell death, offering hope for treating aggressive and drug-resistant cancers.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
A new study examines the mechanisms, clinicopathological features, and management strategies of GI toxicity induced by targeted cancer therapies. The authors highlight the importance of close collaboration between oncologists, gastroenterologists, and pathologists to ensure accurate diagnosis.
Researchers at the Center for Cell-Based Therapy developed a new approach to enhance CAR-NK cell cytotoxicity, combining optimized co-stimulation with reversible pharmacological control. The study showed increased tumor control in animal models, paving the way for improved cancer treatment.
Xiwen Gong and Zhen Xu, both from the University of Michigan Engineering, received the award for developing optoelectronics and histotripsy, a cancer treatment using sound waves. The new treatment can spare patients from chemotherapy and radiation therapy.
Researchers have identified specific changes in genetic material that can predict the effectiveness of chemotherapy in young adults with germ cell tumors. A blood test based on these changes could help doctors make personalized decisions about treatment.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
The Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US. This innovative technology uses heat to damage and kill cancer cells, offering a new angle in cancer treatment and potentially improving outcomes for patients with resistant tumors.
The conference aims to improve genetic studies, clinical best practices and community interventions to combat the increasing cancer incidence rates. It will bring together top cancer-focused minds to promote precision medicine and stimulate multidisciplinary collaborations for cancer solutions.
Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.
Research at University of Seville and CABIMER reveals circadian protein Cryptochrome1 regulates DNA repair in response to time of day. Effective radiotherapy timing found to improve sensitivity of breast and prostate cancers, but not lung or glioma cancers.
Researchers have engineered Listeria bacteria to stimulate the body's innate immune system and eliminate cancer cells. The therapy, which boosts gamma delta T cells, shows promise in treating children with leukemia and preventing graft-versus-host disease.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
The National Comprehensive Cancer Network (NCCN) has committed to updating its robust information resources for cancer patients and caregivers annually, available in both English and Spanish. The updated resources will provide factual, trustworthy information to guide patients and caregivers towards their best possible outcome.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
A team of researchers at VCU Massey Comprehensive Cancer Center has discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. The study found that RBF4...
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
A new AI tool has been developed to predict the chances of death, major bleeding, or another cardiac event in cancer patients who have had a heart attack. The ONCO-ACS score combines cancer-related factors with standard clinical data to provide individualized treatment recommendations.
Researchers developed a new framework called SOLVE to overcome data challenges in precision cancer treatment. By jointly modeling known and unknown factors, SOLVE provides a robust tool for biomarker discovery and investigating tumor responses.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
A large multinational clinical trial found that giving healthcare providers access to patient-reported outcome (PRO) data significantly improves the consistency of how treatment-related side effects are assessed in patients with cancer. This study highlights the importance of integrating the patient's voice into routine clinical evalua...
Research suggests that blocking growth factor receptor signaling using cancer drugs may overcome two challenges: managing oral cancer pain and preventing opioid tolerance. This approach could control cancer while addressing pain through a non-opioid, biologically rational approach.
A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.
Research reveals that chemotherapy alters the gut microbiota, producing indole-3-propionic acid, which travels to the bone marrow and rewires immune cell production. This leads to a metastasis-refractory state in preclinical models and improved survival outcomes in patients with colorectal cancer.
A study published by the National Institutes for Quantum Science and Technology found that carbon-ion radiotherapy provided durable tumor control with minimal side effects while preserving breast appearance in carefully selected patients who were unable or unwilling to undergo surgery. The treatment resulted in excellent local control ...
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
A study from Flinders University found that patients with progressive disease, which describes the way cancer grows, have varying survival rates depending on whether their existing tumours re-grow or new ones appear. Understanding this progression can help doctors make better decisions about future treatment strategies.
Researchers at UMass Amherst create a platform technology to target and destroy cancer-causing proteins, offering tailored treatments for specific cancers. A separate approach delivers fully functional proteins to reprogram cancerous cells, restoring their normal function.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
Large language models (LLMs) provide treatment recommendations for early-stage hepatocellular carcinoma (HCC) that align with clinical guidelines. However, their performance is limited in late-stage disease, where they prioritize tumor factors over liver function. LLMs should be used as a supplement to clinical expertise.
A machine learning model has identified the most important drivers of cancer survival in nearly all countries, highlighting factors such as national wealth, access to radiotherapy and universal health coverage. The model provides data-driven roadmaps for policymakers to prioritize resources and close survival gaps.
Researchers developed an algorithm using whole-genome sequencing to detect homologous recombination deficiency, a type of DNA-repair defect vulnerable to PARP inhibitors. The approach identified genetic mutations beyond BRCA1 and BRCA2, promising more accurate patient selection for cancer treatment.
A new clinical trial, PAGODA, seeks to minimize treatment interruptions and help patients complete their chemotherapy as planned. The trial will test a structured plan to guide doctors in making small, proactive changes to chemotherapy doses to prevent treatment delays.
A Mass General Brigham study identifies new mutations that emerge in tumor cells following treatment, driving resistance in patients with different types of cancer. The researchers found two main categories of mutations: those impairing p53 function and others disrupting drug binding, highlighting a path forward for overcoming resistance.
Researchers at University of British Columbia have successfully grown specialized immune cells called helper T cells from stem cells in a controlled laboratory setting. This breakthrough could lead to more accessible and effective off-the-shelf treatments for various conditions, including cancer, autoimmune disorders, and infectious di...
The Mount Sinai Health System has launched an AI-powered clinical trial-matching platform, PRISM, to help connect patients with life-saving trials. The platform uses machine learning to match patients with trials based on their electronic health records and diagnosis.
The collaboration aims to integrate AI-powered analytics with clinical expertise to accelerate data-driven cancer care. MD Anderson researchers will leverage SOPHIAs AI technologies to develop bioinformatics pipelines for rapid RNA-sequencing data interpretation.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
Two studies found that elevated bacteria levels in tumors weaken immune response, driving resistance to immunotherapy. Researchers are now exploring how to identify patients most likely to benefit from immunotherapy and develop targeted interventions to restore its effectiveness.
Researchers create a novel mathematical framework to control biological noise, enabling precise single-cell control. The 'Noise Robust Perfect Adaptation' technology suppresses stochastic fluctuations while maintaining stable average behavior, with promising applications in cancer therapy and synthetic biology.
A new study from Texas A&M University reveals that circadian disruptions change the structure of mammary glands, weaken immune defenses, and fuel aggressive breast cancer. Disabling an immune checkpoint molecule called LILRB4 helps restore the immune system's ability to fight back.
A new study by researchers from the Germans Trias i Pujol Research Institute provides a comparative analysis of the impact of BRAF gene mutations in melanoma and colorectal cancer. The review highlights molecular, cellular, and tumour microenvironment factors that explain the therapeutic dichotomy between the two tumour types.
Researchers at MD Anderson Cancer Center have found that inhibiting GFER, a mitochondrial enzyme, in combination with immune checkpoint blockade improves antitumor response in preclinical models. This two-pronged approach holds promise for patients with pancreatic cancer.
Researchers at UT Health San Antonio are developing APOBEC inhibitors to block tumor mutation rates and slow cancer's evolution. The goal is to strengthen current therapies and improve their long-term effectiveness.
Proton therapy has been shown to provide a significant survival benefit for patients with head and neck cancers. In another study, researchers have identified a promising target for treating pancreatic cancer by inhibiting the mitochondrial enzyme GFER. Additionally, diagnostic breast MRI may be unnecessary for some patients with early...
Researchers at IIT identified a candidate molecule called Apt1 that enhances existing anticancer therapies by making tumour cells more vulnerable to chemotherapy drugs. The molecule slows DNA repair and impairs the interaction between RAD51 and BRCA2 proteins, inducing synthetic lethality in cancerous cells.
Researchers at EPFL have developed two bioengineering approaches that exploit extracellular vesicles to train dendritic cells to identify cancer cells without the need for tumor material. The approaches, published in Nature Communications and Science Translational Medicine, show promising results in enhancing cancer immunotherapy.
Researchers at Rockefeller University discovered that the T cell receptor springs open when activated by an antigen, contrary to previous studies. This finding could lead to next-generation treatments for a broader group of cancer patients.
Researchers at the University of Geneva have created a laboratory platform to rapidly evaluate the toxicity of new cancer treatments using human tissue-derived cell clusters. This approach allows for safer evaluation and could lead to personalized treatment options.